Core Viewpoint - iRhythm Holdings, Inc. is set to release its financial results for Q4 and the full year 2025 on February 19, 2026, with a conference call scheduled for the same day [1]. Company Overview - iRhythm is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3]. - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3]. - iRhythm aims to enhance patient care by delivering better data, insights, and health outcomes [3]. Investor Information - Interested parties can access a live and archived webcast of the upcoming conference call on the company's investor website [2]. - The investor contact for inquiries is Stephanie Zhadkevich [4].

Core Insights - iRhythm Holdings (NASDAQ: IRTC) is recognized as one of the top 12 Medical Devices stocks favored by hedge funds [1] - Morgan Stanley maintains an Overweight rating on iRhythm Holdings with a price target of $205, indicating a 35% upside potential from current levels [1] - The company reported preliminary fourth-quarter revenues of approximately $207 million, exceeding consensus estimates of $200 million [2] - iRhythm's 2026 revenue guidance projects a midpoint of around $875 million, excluding contributions from its next-generation Mobile Cardiac Telemetry (MCT) device [2] - Vijay Kumar from Evercore ISI upgraded his rating for iRhythm Holdings to Outperform, raising the price target from $194 to $210, suggesting an upside potential of over 38% [3] - iRhythm Holdings specializes in digital healthcare, focusing on device-based Zio biosensor technology for diagnosing cardiac arrhythmias, and offers both long-term and short-term cardiac monitoring services [4] Company Overview - iRhythm Holdings develops and commercializes Zio biosensor technology for cardiac arrhythmia diagnosis [4] - The company provides mobile cardiac telemetry monitoring and incorporates AI-based data analytics into its operations [4]

Core Viewpoint - IRHYTHM HLDGS (IRTC) shares experienced a 5% increase, closing at $163.24, following positive investor sentiment driven by preliminary fourth quarter operational highlights and expectations for strong revenue growth in 2025 [1][2]. Group 1: Company Performance - The company anticipates full year 2025 revenue to exceed the high end of its previous guidance of $740 million, attributed to record revenue unit volume in Q4 2025 [2]. - The Zacks Consensus Estimates project full year 2025 sales at $738.6 million, reflecting a year-over-year growth of 24.8% [2]. - For the upcoming quarterly report, the company is expected to post earnings of $0.02 per share, indicating a 100% year-over-year increase, with revenues projected at $200.3 million, a rise of 21.9% from the previous year [3]. Group 2: Earnings Estimates and Market Sentiment - The consensus EPS estimate for the quarter has been revised 0.6% higher in the last 30 days, suggesting a positive trend that typically correlates with stock price appreciation [4]. - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4]. - In the same industry, Clover Health Investments (CLOV) saw a 10.6% increase in its stock price, closing at $2.81, despite a -3.8% return over the past month [4].

Core Insights - iRhythm Technologies Inc. anticipates full-year 2025 revenue to exceed $740 million, driven by record revenue unit volume in Q4 2025, surpassing analysts' consensus of $737.95 million [1] - For fiscal year 2026, iRhythm expects revenue between $870 million and $880 million, reflecting a year-over-year growth of approximately 17% to 18%, compared to the consensus of $862.68 million [2] - The company projects an adjusted EBITDA margin of approximately 11.5% to 12.5% for 2026 [2] Growth Catalysts - iRhythm is positioned to accelerate growth through multiple catalysts, including deeper penetration in primary care and population health via AI-powered risk stratification partnerships, momentum in mobile cardiac telemetry, expansion into adjacent markets like obstructive sleep apnea, and continued international execution [3] Market Reaction - Following the update, iRhythm's stock fell around 20%, attributed to the delay of the Zio MCT launch to 2027 and formal 2026 guidance that did not meet market expectations [4] - Analyst Brandon Vazquez believes the stock weakness is overblown and recommends buying shares, adding iRhythm to the William Blair Analyst Conviction List due to favorable growth prospects and valuation reset [5] Management Insights - Management had previously hinted at a delay for Zio MCT, and the recent conference made this explicit, leading to adjustments in buy-side models regarding MCT contributions in 2026 [6] - William Blair does not foresee any FDA issues that iRhythm cannot address in a reasonable timeframe, and the expected 2027 launch allows for flexibility in case of additional agency requests [6] Stock Performance - iRhythm shares were trading at $155.44, up 1.23% at the time of publication, indicating some recovery amidst the recent stock volatility [7]

Core Insights - The company expects revenue for full year 2026 to be approximately $870 million to $880 million, reflecting a year-over-year growth of about 17% to 18% [1] - The anticipated adjusted EBITDA margin for 2026 is projected to be around 11.5% to 12.5% [1] - The year 2025 has been described as transformative for the company, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time [1] Company Performance - The company has executed strong commercial volumes and aims to drive best-in-class quality systems [1] - The comprehensive clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of Zio LTCM and market expansion [1] - The company is well-positioned for growth with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [1] Market Expansion - The company plans to expand into adjacent markets such as obstructive sleep apnea and continue its international execution [1] - There is a focus on mobile cardiac telemetry and leveraging AI-powered risk stratification partnerships to enhance market presence [1] - The company expresses confidence in delivering sustainable, profitable growth while transforming cardiac care for millions of patients globally [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - iRhythm is optimistic about its performance in 2026 following a successful 2025, indicating strong growth potential in the medtech industry [2]. Company Insights - The management team of iRhythm, including CEO Quentin Blackford and CFO Dan Wilson, presented at a JPMorgan Medtech event, highlighting the company's achievements and future outlook [1]. - iRhythm focuses on the complexities of arrhythmia signals, which present both challenges and opportunities in the healthcare space [3]. Industry Context - The presentation emphasized the importance of accurately interpreting arrhythmia signals, which can manifest in various ways, underscoring the need for advanced diagnostic solutions in the medtech sector [3].

iRhythm Technologies (NasdaqGS:IRTC) FY Conference Summary Company Overview - **Company**: iRhythm Technologies - **Industry**: MedTech, specifically in cardiac monitoring and arrhythmia detection - **Conference Date**: January 12, 2026 Key Points and Arguments Financial Performance - iRhythm achieved over **$740 million** in revenue for 2025, exceeding guidance and marking the first profitable year in the company's history [10][35] - The company expects **$870-$880 million** in revenue for 2026, representing a growth of **17%-18%** [35] - For the first time, iRhythm will be **free cash flow positive** in 2025, with an expected **11.5%-12.5%** adjusted EBITDA margin for 2026 [35][36] Market Opportunity - There are **27 million undiagnosed individuals** with cardiac arrhythmias in the U.S., representing a significant market opportunity [5][11] - iRhythm currently holds **72% market share** in long-term cardiac monitoring (LTCM) and aims to expand its presence in the **Mobile Cardiac Telemetry (MCT)** space, where it has only **15% market share** [13][24] - The company is targeting a **30 million test** market opportunity, including both undiagnosed patients and international markets [12][13] Product and Technology - iRhythm's **Zio** monitoring system allows patients to wear a device for **14 days**, capturing nearly **1.5 million heartbeats** [8] - The company is developing a **third-generation algorithm** for arrhythmia detection, which is currently with the FDA [9] - iRhythm is leveraging **AI** to analyze **3 billion hours** of heartbeat data, enhancing predictive capabilities for undiagnosed arrhythmias [22][27] Strategic Initiatives - The company is focusing on expanding into **primary care**, with over **20% of prescribing** now coming from this channel [17] - iRhythm is collaborating with **innovative channel partners** to target comorbid disease states, which overlap significantly with arrhythmias [20] - The company is also exploring opportunities in adjacent markets such as **sleep apnea**, where there is a high correlation with arrhythmias [32][33] Competitive Landscape - iRhythm has a competitive advantage due to its established product in LTCM, while competitors primarily focus on MCT, making it difficult for them to penetrate the primary care market [52][53] - The company has been successful in integrating with **EHR systems**, which has led to a **20%-25% increase** in volume post-integration [30] Research and Evidence Generation - iRhythm has published over **135 research manuscripts**, with nearly **40 peer-reviewed**, establishing a strong evidence base for its products [11][12] - The company emphasizes the cost savings associated with early arrhythmia detection, estimating **$15-$17 million** in savings for every **1,000 patients** identified [32] Future Outlook - iRhythm is optimistic about its growth trajectory, with plans to continue investing in technology and market expansion while maintaining profitability [36][59] - The company aims to achieve **15% adjusted EBITDA margins** as it approaches **$1 billion** in revenue [37] Additional Important Insights - The company is addressing **capacity constraints** in the healthcare system by moving monitoring to primary care, where there is a significant shortage of cardiologists [6][17] - iRhythm's proactive approach to identifying undiagnosed patients through AI and data analysis is seen as a game changer in the industry [23][27] - The company is currently working on enhancing its MCT product to meet market demands for longer monitoring durations [24][46] This summary encapsulates the key points discussed during the iRhythm Technologies FY Conference, highlighting the company's financial performance, market opportunities, product innovations, strategic initiatives, competitive landscape, and future outlook.

Financial Performance & Market Position - Anticipated full year 2025 revenue is over $740 million[30], reflecting strong commercial adoption and market expansion[83] - The company expects $870 million to $880 million in global net revenue for 2026[86] - The company anticipates an adjusted EBITDA margin of 825% to 875% for 2025[83], and projects 115% to 125% for 2026[87] - The company holds a 72% market share in Long-Term Continuous Monitoring (LTCM) within the US[39] Market Opportunity & Expansion - There are over 27 million potential patients in the United States who could benefit from ambulatory cardiac monitoring[32] - The company sees a $500 million revenue opportunity in converting 19 million legacy technology tests still performed in the US[39] - The company has a 15% market share in Mobile Cardiac Telemetry (MCT), with each 10 points of share representing $80 million to $100 million[39] - The company is targeting 32 million ambulatory cardiac monitoring tests across prioritized EU and APAC countries[32] Clinical & Technological Advancements - The company has generated over 12 million patient reports since its inception through December 31, 2025[34] - The company has accumulated approximately 3 billion hours of curated ECG data since its inception through 2025[36] - Approximately 85% of patients in representative customer programs had at least one arrhythmia identified[53]

Core Insights - iRhythm Technologies, Inc. has reported a transformative year in 2025, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time in its history [3] Operational Highlights - The company has recorded strong commercial volumes and is well-positioned for growth in 2026 with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [3] - iRhythm's clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of its Zio LTCM product, which is expected to expand into additional populations and care settings [3] Financial Outlook - For full year 2025, revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025 [7] - The company expects revenue for 2026 to be approximately $870 million to $880 million, representing a year-over-year growth of about 17% to 18%, with an adjusted EBITDA margin of approximately 11.5% to 12.5% [7] Clinical Evidence - Recent real-world evidence from over 1.4 million patients reinforces the clinical superiority of Zio LTCM, with data demonstrating consistent performance in Asian populations and validating successful at-home self-application for earlier detection in at-risk populations [7]